SPC189
Olaratúmab
Status:
VeittApplication date:
5.4.2017Application published:
15.5.2017Grant published:
15.5.2019
Max expiry date:
18.6.2031Next due date:
30.6.2026Medicine name:
LartruvoMedicine for children:
No
Timeline
Today
5.4.2017Application
15.5.2017Publication
15.5.2019Registration
18.6.2031Expires
Marketing license
IS authorization number:
EU/1/16/1143/001Date:
1.12.2016
Foreign authorization number:
EU/1/16/1143Date:
9.11.2016
Owner
Name:
ImClone LLCAddress:
450 East 29th Street, 12th Floor, New York US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2100614